Raymond James Financial Inc. Takes $568,000 Position in REGENXBIO Inc. (NASDAQ:RGNX)

Raymond James Financial Inc. bought a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 73,510 shares of the biotechnology company's stock, valued at approximately $568,000. Raymond James Financial Inc. owned about 0.15% of REGENXBIO at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. JPMorgan Chase & Co. raised its position in REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after buying an additional 1,659,206 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after purchasing an additional 296,700 shares during the period. Barclays PLC boosted its holdings in REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company's stock valued at $1,217,000 after purchasing an additional 67,948 shares in the last quarter. Wells Fargo & Company MN increased its position in REGENXBIO by 34.0% during the 4th quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock worth $374,000 after purchasing an additional 12,285 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after buying an additional 2,510 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.

REGENXBIO Stock Down 3.0%

Shares of RGNX traded down $0.25 during trading hours on Wednesday, reaching $7.94. 292,975 shares of the company traded hands, compared to its average volume of 1,039,804. The stock has a fifty day simple moving average of $7.39 and a 200 day simple moving average of $7.99. The stock has a market capitalization of $397.68 million, a PE ratio of -1.57 and a beta of 1.11. REGENXBIO Inc. has a fifty-two week low of $5.03 and a fifty-two week high of $16.85.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to analysts' expectations of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Research analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. HC Wainwright dropped their price objective on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. The Goldman Sachs Group cut their price target on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Chardan Capital reissued a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Finally, Raymond James started coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.